Apogee Therapeutics (APGE)

• Market cap: $2.11B
• 1 day: 0.98%
• 5 days: -9.61%
• 1 month: -22.94%
• 3 months: -34.09%
• 6 months: -24.69%
• Year to date: -21.40%
• 1 year: 17.28%
• 5 years: 74.56%
• 10 years: 74.56%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Employees: 91

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]

54% more capital invested

Capital invested by funds: $2.14B [Q2] → $3.29B (+$1.15B) [Q3]

3.72% more ownership

Funds ownership: 121.01% [Q2] → 124.72% (+3.72%) [Q3]

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

0% more funds holding

Funds holding: 139 [Q2] → 139 (+0) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 47

83% less call options, than puts

Call options by funds: $2.65M | Put options by funds: $15.2M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $89 140% upside
• Avg. target: $90 142% upside
• High target: $90 143% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Wedbush David Nierengarten 38% 1-year accuracy 48 / 126 met price target	143% upside $90	Outperform Maintained	2 Dec 2024
Canaccord Genuity Edward Nash 56% 1-year accuracy 10 / 18 met price target	140% upside $89	Buy Initiated	25 Nov 2024